MindWalk Holdings (HYFT) Cash from Investing Activities (2023 - 2026)
MindWalk Holdings (HYFT) reported Cash from Investing Activities of -$9.3 million for Q1 2026, down 11670.84% year-over-year from N/an in Q1 2025, and down 17308.74% quarter-over-quarter from -$53345.0 in Q4 2025.
MindWalk Holdings (HYFT) Cash from Investing Activities (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has 4 years of Cash from Investing Activities data on file, last reported at -$9.3 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$9.3 million, down 11670.84% year-over-year; the trailing twelve-month figure through Jan 2026 was -$10.0 million (down 780.94% YoY), and the FY2025 annual result was -$573592.0, up 50.24% from the prior year.
- Cash from Investing Activities eased to -$9.3 million in Q1 2026 per HYFT's latest filing, from -$53345.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $42164.1 in Q1 2024 and troughed at -$9.3 million in Q1 2026.
- A 4-year average of -$922600.2 and a median of -$192072.0 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2026: Cash from Investing Activities surged 125.16% in 2024, then tumbled 11670.84% in 2026.
- A 4-year view of Cash from Investing Activities shows it stood at -$230098.1 in 2023, then jumped by 79.31% to -$47598.8 in 2024, then declined by 12.07% to -$53345.0 in 2025, then sank by 17308.74% to -$9.3 million in 2026.
- Business Quant data shows HYFT's Cash from Investing Activities at -$9.3 million in Q1 2026, -$53345.0 in Q4 2025, and -$432304.5 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 579,519.10 |
| 10 | MindWalk Holdings | 166.20 Mn | 156.06 Mn | 1.78 | -9.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -9.29 Mn |
| Jan 31, 2026 | -9.29 Mn |
| Oct 31, 2025 | -53,345.05 |
| Oct 31, 2025 | -53,345.05 |
| Jul 31, 2025 | -432,304.49 |
| Jul 31, 2025 | -432,304.49 |
| Apr 30, 2025 | -252,279.60 |
| Apr 30, 2025 | -252,279.60 |
| Jan 31, 2025 | -78,895.81 |
| Jan 31, 2025 | -78,895.81 |
| Oct 31, 2024 | -47,598.77 |
| Oct 31, 2024 | -47,598.77 |
| Jul 31, 2024 | -192,072.05 |
| Jul 31, 2024 | -192,072.05 |
| Apr 30, 2024 | -819,385.03 |
| Apr 30, 2024 | -819,385.03 |
| Jan 31, 2024 | 42,164.12 |
| Jan 31, 2024 | 42,164.12 |
| Oct 31, 2023 | -230,098.09 |
| Oct 31, 2023 | -230,098.09 |